Intercept Pharmaceuticals, Inc. is shifting guidance for an announcement of the Phase 3 REVERSE trial in NASH patients with compensated cirrhosis from YE17 to 1Q18.{https://www.sec.gov/Archives/edgar/data/1270073/0001144204red17red065549/0001144204-17-065549-index.htm}